Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
3 pending office actions • 3 art units • 3 examiners • 0 of 3 (0%) have an AI response strategy ready
Intellexon GmbH is currently managing 3 pending office actions within the Biotechnology & Pharmaceuticals technology area. These 3 actions are distributed across 3 distinct examiners and 3 distinct art units, indicating a diversified prosecution strategy. BATES, KEENAN ALEXANDER is the busiest examiner for the portfolio, though they are responsible for only 1 pending action.
This distribution across 3 distinct art units suggests that the company's intellectual property covers diverse facets of biotechnology. Because each of the 3 pending office actions is assigned to a different examiner, the practitioner cannot rely on a single examiner's feedback to predict outcomes for the other applications. The portfolio requires a multifaceted approach to address the unique requirements of 3 separate art units simultaneously. This lack of concentration means that the practitioner must be prepared for different examination styles and sets of prior art. Success in 1 art unit will not necessarily translate to success in the others, requiring a tailored strategy for each of the 3 distinct examiners involved.
Based on the USPTO statutory response window for each pending office action. 2 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 + other | 1 (33%) |
| §112 only | 1 (33%) |
| Multi-statute (no §101) | 1 (33%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| BATES, KEENAN ALEXANDER | 1 | 45.5% | +79.5% |
| WILSON, MICHAEL C | 1 | 41.5% | +17.9% |
| BUCHANAN, BAILEY CHEYENNE | 1 | 42.9% | +57.1% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17771662 | HLA CLASS I MOLECULES IN IN VITRO FERTILIZATION AND FURTHER MEDICAL IMPLICATIONS | BATES, KEENAN ALEXANDER | 19d |
| 17624791 | DETERMINING INDIVIDUAL HLA PATTERNS, USE AS PROGNOSTICATORS, TARGET GENES AND THERAPEUTIC AGENTS | BUCHANAN, BAILEY CHEYENNE | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 3 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17625063 | HLA-H IN MEDICINE AND DIAGNOSTICS | WILSON, MICHAEL C | 49d overdue |
| 17771662 | HLA CLASS I MOLECULES IN IN VITRO FERTILIZATION AND FURTHER MEDICAL IMPLICATIONS | BATES, KEENAN ALEXANDER | 19d |
| 17624791 | DETERMINING INDIVIDUAL HLA PATTERNS, USE AS PROGNOSTICATORS, TARGET GENES AND THERAPEUTIC AGENTS | BUCHANAN, BAILEY CHEYENNE | — |
| Art Unit | Apps |
|---|---|
| 1631 | 1 |
| 1638 | 1 |
| 1682 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 17771662 | HLA CLASS I MOLECULES IN IN VITRO FERTILIZATION AND FURTHER MEDICAL IMPLICATIONS | BATES, KEENAN ALEXANDER | 1631 | §102§112 | Final Rejection | 19d | Pending | Apr 25, 2022 |
| 17625063 | HLA-H IN MEDICINE AND DIAGNOSTICS | WILSON, MICHAEL C | 1638 | §112Other | Final Rejection | 49d overdue | Pending | Jan 05, 2022 |
| 17624791 | DETERMINING INDIVIDUAL HLA PATTERNS, USE AS PROGNOSTICATORS, TARGET GENES AND THERAPEUTIC AGENTS | BUCHANAN, BAILEY CHEYENNE | 1682 | §101§102§103 | Final Rejection | — | Pending | Jan 04, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial